Century Therapeutics, Inc. Stock Analysis & AI Score
Century Therapeutics, Inc. (IPSC) has an ST Score of 45.2 (C+), driven by its Forecast (A) and held back by its Momentum (D+). Analysts rate it Buy with a $7.50 price target (+349.1% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Century Therapeutics, Inc. (IPSC) has an ST Score of 45.2 (C+), driven by its Forecast (A) and held back by its Momentum (D+). Analysts rate it Buy with a $7.50 price target (+349.1% upside).
- Strongest
- ForecastA
- Weakest
- MomentumD+
All factor grades
- ForecastA
- ProfitabilityB-
- GrowthB-
- Financial StrengthC+
- ValuationC
- MomentumD+
- Piotroski1/9
Contact
IPSC stock: frequently asked questions
What is IPSC's ST Score?
Century Therapeutics, Inc. (IPSC) has an ST Score of 45.2 (C+), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is IPSC a buy, hold, or sell?
Analysts rate IPSC a Buy, with a price target of $7.50 (+349.1% vs the current price). Our ST Score grades it C+ (45.2/100). The ST Score is a data-driven signal, not a recommendation.
What are IPSC's factor grades?
Valuation C, Profitability B-, Financial Strength C+, Momentum D+, Growth B-, Forecast A.
What is IPSC's valuation grade?
Century Therapeutics, Inc. (IPSC) earns a valuation grade of C, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is IPSC's growth grade?
Century Therapeutics, Inc. (IPSC) earns a growth grade of B-, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is IPSC's profitability grade?
Century Therapeutics, Inc. (IPSC) earns a profitability grade of B-, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is IPSC's financial strength grade?
Century Therapeutics, Inc. (IPSC) earns a financial strength grade of C+, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for IPSC?
The average analyst price target for Century Therapeutics, Inc. (IPSC) is $7.50 from 9 analysts, which is +349.1% versus the recent price of $1.67.
What is IPSC's Piotroski score?
Century Therapeutics, Inc. (IPSC) has a Piotroski F-Score of 1 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.